Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #357256 on Anavex Life Sciences Corp (AVXL)
nidan7500
04/14/22 9:33 AM
#357262 RE: nidan7500 #357256
As a physician and researcher who investigates the efficacy of medicines, I have been watching this story unfold over the past year. As of right now, I am certain of one thing: With 6 million people in the United States suffering from Alzheimer’s, and current treatments only marginally effective, there is a desperate need for medications that can slow the disease. But the evidence on Aduhelm so far is contradictory. Two Phase III clinical trials were stopped early after an independent committee, appointed by Biogen, analyzed the data and reported the studies were unlikely to show Aduhelm would demonstrate a benefit. This is not unusual; clinical trials are often stopped when early data suggests a drug will not work